Loss of Wild-Type CDKN2A Is an Early Event in the Development of Melanoma in FAMMM Syndrome

J Invest Dermatol. 2020 Nov;140(11):2298-2301.e3. doi: 10.1016/j.jid.2020.03.938. Epub 2020 Mar 28.

Authors

Eirini Christodoulou¹, Rogier J Nell², Rob M Verdijk³, Nelleke A Gruis¹, Pieter A van der Velden², Remco van Doorn⁴

Affiliations

¹ Department of Dermatology, LUMC, Leiden, the Netherlands.
² Department of Ophthalmology, LUMC, Leiden, the Netherlands.
³ Department of Pathology, LUMC, Leiden, the Netherlands; Department of Pathology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.
⁴ Department of Dermatology, LUMC, Leiden, the Netherlands. Electronic address: [email protected].

PMID: 32234459
DOI: 10.1016/j.jid.2020.03.938

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cyclin-Dependent Kinase Inhibitor p16 / genetics*
Dysplastic Nevus Syndrome / genetics*
Humans
Loss of Heterozygosity*
Melanoma / etiology*
Melanoma / genetics
Melanoma / pathology
Polymorphism, Single Nucleotide

Substances

CDKN2A protein, human
Cyclin-Dependent Kinase Inhibitor p16